[An antiemetic effect of methylprednisolone plus droperidol against nausea and vomiting caused by administration of high-dose adriamycin to breast carcinoma patients].
An antiemetic combination of methylprednisolone and droperidol was administered to 10 patients with breast cancer showing postoperative recurrence, receiving high-dose adriamycin. Methylprednisolone was given twice intravenously at a dose of 500 mg, before and after administration of adriamycin, and droperidol was given just before administration of adriamycin. The 10 patients received a total of 20 chemotherapy courses. Complete relief of vomiting was achieved in 95% of these 20 courses, and mild nausea occurred in 40%. Side effects were drowsiness, acne and akathisia, which were minimal. It was concluded that an antiemetic combination of methylprednisolone and droperidol was very effective for prevention of high-dose adriamycin-induced nausea and vomiting.
D000328:Adult; D000932:Antiemetics / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000009:adverse effects*; D004329:Droperidol / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D009364:Neoplasm Recurrence, Local; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000932:Antiemetics; D004317:Doxorubicin; D004329:Droperidol; D008775:Methylprednisolone